1/23 We are excited to announce that our most recent study “In vivo dendritic cell reprogramming for cancer immunotherapy” was published in @ScienceMagazine.

Here is a summary of what we discovered!science.org/doi/10.1126/sc… 2/23 By delivering transcription factors PU.1, IRF8 and BATF3 (PIB), we successfully reprogrammed tumor cells in vivo within the immunosuppressive tumor microenvironment (TME) into antigen-presenting conventional dendritic cells type 1 (cDC1s) critical for robust immune responses